Please login to the form below

Not currently logged in
Email:
Password:

Rigel Pharmaceuticals

This page shows the latest Rigel Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

The FDA gave the go-ahead to a pair of rare disease therapies this week, both marking the first-ever approvals for developers Rigel Pharmaceuticals and Ultragenyx. ... Rigel is also developing it for additional indications, including autoimmune

Latest news

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... In August, Rigel reported the same 18

  • Rigel plans job cuts in R&D restructure Rigel plans job cuts in R&D restructure

    Follows failure of fostamatinib disodium in rheumatoid arthritis trial. Rigel Pharmaceuticals plans to cut 30 jobs as part of a restructure of its research efforts following the failure of fostamatinib disodium ... Rigel said it expects to advance one of

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    Pharma and Omthera Pharmaceuticals. ... Other respiratory prospects for AZ include the JAK inhibitor R256 licensed last year from Rigel Pharmaceuticals in a deal that could be worth up to $100m.

  • Pfizer returns asthma drug to Rigel

    Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals. ... Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals as part of a larger decision to move away from

  • AZ's phase III RA trial underway

    Fostamatinib was initially developed by Rigel Pharmaceuticals, with AZ purchasing rights to further develop and commercialise the drug in February 2010.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Salix Pharmaceuticals/ Valeant Pharmaceuticals. GI products. Corporate acquisition. 14, 500. Flexus Biosciences/ BMS. ... Collaboration - develop and commercialise. 342. Rigel Pharmaceuticals/ BMS. Small molecule TGF beta receptor kinase inhibitors -

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics